Vaximm AG, an OSR Company, Announces Forthcoming Publication of Cross-Indication Clinical Data for VXM01, Its VEGFR-2-Targeted Cancer Vaccine Platform

Encouraging data from two glioblastoma studies are expected to be submitted for publication in the coming months

BELLEVUE, WA / ACCESS Newswire / August 3, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today announced that its subsidiary Vaximm AG has completed the analysis of results from two clinical studies evaluating VXM01, an oral DNA vaccine targeting the vascular endothelial growth factor receptor 2 (VEGFR-2), in patients with recurrent glioblastoma.